Bovine Herpesvirus Type 1 (BHV-1/IBR)

Antiserum

<table>
<thead>
<tr>
<th>Catalog No.</th>
<th>PAB-IBR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot</td>
<td>P220314-001</td>
</tr>
<tr>
<td>Expiration</td>
<td>24 March 2026</td>
</tr>
</tbody>
</table>

Quality Control Method: Indirect FA using BHV-1/IBR 12-well slide (catalog no. SLD-IFA-IBR), and anti-caprine IgG FITC conjugate (catalog no. CJ-F-CAPG-10ML).

Specific Reaction: 1–3+ signal at a 1/400 dilution with no background. Endpoint titer is greater than 1/6,400 dilution.

Other Comments: NA

QC Manager: David Hyatt

Pattern Of Fluorescence: Primarily undifferentiated cytoplasmic with some nuclear fluorescence, especially in rounded cells and degenerating cells in plaques with acellular centers.

FA Cross-Reaction Screening: The Antiserum has also been screened by FA and has been found to react with Bovine Adenovirus Type 1 (BAV-1), at 1–4+, Reovirus (REO) at 1–2+ and Toxoplasma gondii at 1+ at a screening dilution of 1/50, but does not react with Bovine Adenovirus 3, and 5 (BAV-3, and 5), Bovine Coronavirus (BCV), Bovine Leukemia Virus (BLV), Bovine Parvovirus (BPV), Bovine Respiratory Syncytial Virus (BRSV), Bluetongue Virus (BTV), Bovine Viral Diarrhea Virus (BVDV), Parainfluenza Virus Type 3 (PI-3), Rabies Recombinant Nucleoprotein (rNP), Vesicular Stomatitis Virus Indiana and New Jersey strains (VSV).

Technical Data Sheet Version: 1

FOR IN VITRO LABORATORY USE ONLY.

29 March 2022